Pipeline
We are developing a diverse pipeline of TCR-T cell therapies to target challenging solid tumours, including those that current adoptive cell therapy options cannot treat. Our goal is to create effective treatments for hard-to-treat cancers, addressing unmet medical needs.
Transforming Treatment for Hard-to-Treat Tumours
At Pan Cancer T, we’re transforming cancer treatment with our TCR-T cell therapy pipeline. Our mission is to tackle difficult solid tumours, especially those lacking effective treatment options. With our lead candidate, PCT1:CO-STIM, we aim to bring hope to patients with triple-negative breast cancer (TNBC) by targeting a specific antigen for improved efficacy and reduced side effects. Our pipeline also includes additional novel targets, TCRs, and next-generation solutions that will offer further therapies and partnering opportunities.
PCT1:CO-STIM
Our Lead Clinical Program
Our lead product, PCT1:CO-STIM, features an IP-protected TCR against a novel target expressed in over 90% of TNBC and melanoma patients. It also incorporates our proprietary TCR:CO-STIM technology to overcome immune suppression in solid cancers.
Preclinical data demonstrates strong safety and efficacy, positioning PCT1:CO-STIM for a first-in-human clinical trial in TNBC, offering new hope to patients with limited options.
How PCT1:CO-STIM stands out
Tumor-Specific and Long-Lasting Therapy
Targeting ROPN1, expressed predominantly in TNBC and melanoma, PCT1:CO-STIM offers highly specific, single treatment designed for enhanced durability in challenging tumours.
Enhanced Efficacy and Reduced Side Effects
Leveraging the body’s immune system, PCT1:CO-STIM aims to achieve complete tumour eradication with minimal side effects, similar to the successes seen in leukemia CAR-T therapies.
Impact on Patient Quality of Life
Aiming for single-dose effectiveness, PCT1:CO-STIM could dramatically reduce ongoing treatment burdens and improve life quality for patients
Explore the opportunities of partnering with us.